Medtronic’s operational headquarters in Minneapolis, Minnesota. Courtesy of Medtronic
The company plans to launch the device in Europe late next week, providing competition for AtriCure’s AtriClip product.
By Nick Paul Taylor, Contributor
Dive Brief:
- Medtronic has received a CE mark for its Penditure left atrial appendage exclusion system, the company said Wednesday.
- Penditure, which Medtronic acquired and launched in the U.S. in 2023, is a clip that surgeons use to close the LAA during cardiac surgeries. The LAA is a source of stroke-causing clots in patients with atrial fibrillation.
- AtriCure provides a rival clip that is also implanted during cardiac surgery. Abbott and Boston Scientific sell LAA occlusion devices that are implanted in minimally invasive procedures.
Dive Insight:
Medtronic added Penditure to its portfolio through the acquisition of Syntheon. The company launched the device in the U.S. shortly after inking the takeover. This week, Medtronic said it has sold more than 10,000 Penditure devices globally.
